Jeremy Parker BSc, DPhil

Jeremy Parker obtained a Chemistry BSc from Imperial College, then moved to the University of Oxford, completing a DPhil with Professor Sir Jack Baldwin. After a brief period with Laporte Fine Chemicals at Southampton, he joined AstraZeneca in 1999. He has held numerous roles in Process Chemistry, Analytical Chemistry and External Sourcing including Team Manager Roles within Process Chemistry and Analytical Chemistry. He is currently AstraZeneca’s Principal Scientist for New Modalities and Tissue Targeting, leading the chemistry activities on the development and commercialisation a range of new therapeutic modalities including Antibody Drug Conjugates, Dendrimer Drug Conjugates and Polymer Drug Conjugates. His interests include contemporary synthetic methodology, route selection, linker chemistry and the synthesis of a wide range of New Therapeutic Modalities.